Fundraising Fox
Graymatters
31 employees on LinkedIn · 3 known investors
Find your way into Graymatters
GrayMatters Health develops Prism, an interventional psychiatry suite that uses fMRI-informed EEG digital biomarkers and self-neuromodulation to help patients regulate brain activity linked to conditions such as PTSD and depression. It is sold to psychiatry clinics to augment standard-of-care therapies.
Also known as GrayMatters Health
Investors · 3
J-Impactlisted by J-ImpactPalo Alto
How we know: J-Impact's portfolio page · Not right? Tell us
J-VenturesreportedSilicon Valley · $250K – $1M
How we know: the VCSheet dataset · Not right? Tell us
Key figures
latest reportedHeadcountAug 202631
Company-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Frequently asked questions
- What does Graymatters do?
- GrayMatters Health develops Prism, an interventional psychiatry suite that uses fMRI-informed EEG digital biomarkers and self-neuromodulation to help patients regulate brain activity linked to conditions such as PTSD and depression. It is sold to psychiatry clinics to augment standard-of-care therapies.
- Who are Graymatters's investors?
- Graymatters's investors include J-Impact, Joyance Partners, J-Ventures.